Commodore Capital LP Increases Stake in Palisade Bio to 7.2% via Shares and Warrants

Commodore Capital LP and its affiliates filed a Schedule 13G/A on May 15, 2026, disclosing a 7.2% ownership stake in Palisade Bio, Inc. (PALI). As of March 31, 2026, the filers—including Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz—beneficially own an aggregate of 12,366,776 shares of common stock. This position consists of 7,181,062 shares of common stock held directly and 5,185,714 shares obtainable through the exercise of pre-funded warrants, which are subject to a 9.99% beneficial ownership limitation. This filing represents an increase from a previously reported 0% ownership level. Commodore Capital LP serves as the investment manager to Commodore Master, while Atkinson and Kramarz are managing partners who exercise investment discretion. The filing is a passive investment certification under Rule 13d-1(c), indicating the securities were not acquired to influence or change the control of the issuer. ownership percentages are calculated based on 167,421,702 shares outstanding as of the issuer's most recent quarterly report.